Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
- Citation:
- Blood vol 132 (suppl 1) 151
- Meeting Instance:
- ASH 2018
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- AFT
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3304
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- Peter M. Voorhees Cesar Rodriguez Brandi Reeves Nitya Nathwani Luciano J Costa Yana Lutska Daniela Hoehn Huiling Pei Jon Ukropec Ming Qi Thomas Lin Paul Richardson
- Networks:
- CA043, LAPS-AL002, LAPS-MA036, LAPS-NC007, LAPS-OH007, NC002
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: